Please login to the form below

Not currently logged in
Email:
Password:

Vascepa

This page shows the latest Vascepa news and features for those working in and with pharma, biotech and healthcare.

Pfizer takeover rumour ignites Amarin shares

Pfizer takeover rumour ignites Amarin shares

A StreetInsider report suggests it is preparing to put a bid in for Amarin, hoping to tap into a sales boost for Vascepa (icosapent ethyl) based on the REDUCE-IT trial, ... The aim will be to build the pipeline and also add to revenue growth – and

Latest news

  • The Midas Touch The Midas Touch

    New trial data finds that Vascepa reduces major adverse CV events by 25%. ... Well done Amarin. The practical lesson of Amarin’s Vascepa for the rest of us is hidden in plain sight.

  • Amarin hits jackpot with astonishing heart benefits from fish oil product Amarin hits jackpot with astonishing heart benefits from fish oil product

    Vascepa's effects in patients already treated with statins to lower their LDL cholesterol, who had various cardiovascular risk factors, including persistent elevated trigylcerides. ... patient population with use of Vascepa 4 grams/day as compared to

  • Amarin sues FDA over off-label policy Amarin sues FDA over off-label policy

    the risk of heart disease, even though Vascepa itself has not yet been shown to achieve that objective in trials. ... In the meantime Vascepa is bringing in modest sales, with first-quarter turnover of around $15m, albeit up from $11m a year ago.

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the ... Sales of Vascepa were around $26m in 2013, its first year on

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    Advisory committee wants more data on Vascepa. Shares in Irish company Amarin Corp nosedived yesterday after a US Food and Drug Administration (FDA) advisory committee voted against approval of its fish ... By a 9-2 margin, the panel said it would not

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics